Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Diabetes Metab ; 34(6 Pt 1): 606-11, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19019717

RESUMO

AIM: Insufficient control of cardiovascular risk factors is observed in primary care. The goal of the present study was to evaluate the association of abdominal obesity with achievement of treatment targets for HbA(1c), LDL cholesterol, triglycerides, HDL cholesterol and blood pressure in primary care. METHODS: In this cross-sectional observational epidemiological study, primary-care practitioners completed a questionnaire covering demographic and socioeconomic data, medical history, drug treatment, and clinical and biological characteristics for 3351 patients (1630 men and 1721 women). Therapeutic targets were HbA(1c) <7%, LDL cholesterol <1.6g/L, triglycerides <1.5 g/L and SBP/DBP <140/90 mmHg. Multivariate analyses were performed to assess the relationship between waist circumference and a lack of cardiovascular risk-factor control. RESULTS: The patients' mean ages were 58+/-14 years and 55+/-16 years for men and women, respectively. A large waist circumference was positively and significantly (P<0.0001 for all) associated with diabetes, hypercholesterolaemia, hypertriglyceridaemia, low HDL cholesterol and hypertension. The prevalence of patients not achieving therapeutic targets increased across waist-circumference quartiles. For treated patients, the odds ratios (95% CI) (adjusted for age, gender, education, smoking status and medical specialty) for not achieving treatment targets were 17.6 (2.2-142) for triglycerides, 2.8 (1.3-6.1) for HbA(1c) and 1.4 (0.9-2.0) for blood pressure on comparisons with extreme quartiles of waist-circumference distribution. CONCLUSION: In primary care, a lack of control of triglycerides, HbA(1c) and, to a lesser extent, blood pressure increases with waist circumference independently of confounders. This suggests that abdominal obesity is associated of poor results in the treatment of diabetes and hypertriglyceridaemia.


Assuntos
Doenças Cardiovasculares/epidemiologia , Obesidade/complicações , Médicos/estatística & dados numéricos , Adulto , Idoso , Pressão Sanguínea , Doenças Cardiovasculares/sangue , Doenças Cardiovasculares/etiologia , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Escolaridade , Feminino , França/epidemiologia , Humanos , Hipertrigliceridemia/sangue , Hipertrigliceridemia/epidemiologia , Masculino , Medicina/estatística & dados numéricos , Pessoa de Meia-Idade , Obesidade/sangue , Obesidade/epidemiologia , Medição de Risco , Fatores de Risco , Especialização , Circunferência da Cintura
2.
Ann Cardiol Angeiol (Paris) ; 56(1): 30-5, 2007 Jan.
Artigo em Francês | MEDLINE | ID: mdl-17343036

RESUMO

BACKGROUND: The interaction between the use of percutaneous coronary intervention (PCI) for non-ST-elevation acute coronary syndromes and the use of secondary prevention medications was analysed in the French S-Témoin Registry. METHODS: The population consisted of 2433 patients seen by their cardiologists at an outpatient clinic 2-12 months after non ST-elevation ACS; the survey was carried out from September 2004 to April 2005. RESULTS: Overall, patients undergoing PCI (75% of the population) had higher levels of prescription of recommended secondary prevention medications. Multivariate logistic regression analysis showed that the use and type of coronary intervention (drug eluting versus bare metal stents) was an independent correlate of the use of dual antiplatelet therapy. In addition, time from the acute episode was also a strong correlate of dual antiplatelet therapy. Statins were also more often used in patients with PCI. CONCLUSION: Patients not treated with PCI are less likely to receive appropriate secondary prevention medications after non ST-elevation acute coronary syndromes. Specific efforts should be directed towards these patients, in particular as regards the prescription of dual antiplatelet therapy.


Assuntos
Angioplastia Coronária com Balão , Fármacos Cardiovasculares/uso terapêutico , Infarto do Miocárdio/terapia , Antagonistas Adrenérgicos beta/uso terapêutico , Idoso , Angina Instável/prevenção & controle , Angina Instável/terapia , Bloqueadores dos Canais de Cálcio/uso terapêutico , Quimioprevenção , Prescrições de Medicamentos , Feminino , Seguimentos , França , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/prevenção & controle , Inibidores da Agregação Plaquetária/uso terapêutico , Sistema de Registros , Stents , Síndrome
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA